Elevance Health, Inc. ELV
Verdict: Sell. Fair value $358 against a price of $364 on 6 Jan 2026, 1% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Operating Cash Flow declined by $2.25B (from $8.06B to $5.81B) while Net Income remained flat. The.... The significant divergence between stable Net Income and falling Operating Cash Flow in 2024....
Main risks
- Severe Free Cash Flow Deterioration: FCF has plummeted from $7.28B in 2021 to a TTM figure of $3.77B, a decline of nearly 50%. This indicates a significant weakening in the company's ability to convert profits into cash.
- Consistent Margin Compression: Net margins have declined annually for four consecutive years, from 4.44% in 2021 to 3.38% in 2024, suggesting pricing pressure or rising costs are eroding profitability.
- Extremely Poor Returns on Incremental Capital: The estimated 3-year ROIIC is a very low 1.4%, indicating that capital invested over the past three years has generated minimal returns. This raises serious questions about capital allocation effectiveness.
- Operating Cash Flow declined by $2.25B (from $8.06B to $5.81B) while Net Income remained flat. The...
- The significant divergence between stable Net Income and falling Operating Cash Flow in 2024...
- Intense competitive environment